Leerink Partners analyst Jonathan Chang raised the price target on Genmab A/S (NASDAQ: GMAB) to $39.00 (from $34.00) while maintaining ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE